基本信息 产品详情 公司简介 推荐产品
  • 首页
  • 个人中心
  • 委托采购
  • 采购清单
网站主页 化工产品目录 原料药 血液系统用药 抗凝血药及抗血小板药 利伐沙班 利伐沙班
  • 利伐沙班|T1184

利伐沙班|T1184

Rivaroxaban
366789-02-8
￥3490 200瓶 起订
￥559 1瓶 起订
￥762 10瓶 起订
￥2350 100瓶 起订
￥213 1瓶 起订
￥1580 50瓶 起订
￥5570 500瓶 起订
￥527 5瓶 起订
￥293 2瓶 起订
￥1210 25瓶 起订
上海 更新日期：2024-09-14

TargetMol中国（陶术生物）

VIP12年
联系人：邵小姐
电话：021-021-33632979拨打
手机：15002134094 拨打
邮箱：marketing@targetmol.com

产品详情:

中文名称：
利伐沙班
英文名称：
Rivaroxaban
CAS号：
366789-02-8
品牌：
TargetMol
产地：
美国
保存条件：
Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
纯度规格：
99.69%
产品类别：
抑制剂
货号：
T1184

Product Introduction

Bioactivity

名称Rivaroxaban
描述Rivaroxaban (BAY 59-7939) is an orally bioavailable oxazolidinone derivative and direct inhibitor of the coagulation factor Xa with anticoagulant activity. Upon oral administration, rivaroxaban selectively binds to both free factor Xa and factor Xa bound in the prothrombinase complex. This interferes with the conversion of prothrombin (factor II) to thrombin and eventually prevents the formation of cross-linked fibrin clots. Rivaroxaban does not affect existing thrombin levels.
细胞实验LLC-PK1 and L-MDR1 cells are seeded in 96-well culture plates with microporous polycarbonate inserts and grown for 4 days in the same medium as used for cell cultures but without vincristine. The medium is replaced every 2 days. Before running the assay, the culture medium is replaced by HBSS buffer supplemented with 10 mM HEPES. Rivaroxaban are dissolved in DMSO and diluted with transport buffer to the respective final test concentrations (final DMSO concentration is always 1%). For inhibitor studies, the inhibitor is added at the appropriate concentration. counted. After 2 hour incubation at 37 °C, samples are taken from both compartments and, after the addition of ammonium acetate buffer and acetonitrile, are analyzed by LC-MS/M (Only for Reference)
激酶实验Factor Xa Activity : The activity of Rivaroxaban against purified serine proteases is measured using chromogenic or fluorogenic substrates in 96-well microtiter plates. The enzymes are incubated with Rivaroxaban or its solvent, dimethyl sulfoxide (DMSO), for 10 minutes. The reactions are initiated by the addition of the substrate, and the color or fluorescence is monitored continuously at 405 nm using a Spectra Rainbow Thermo Reader, or at 630/465 nm using a SPECTRAfluor plus, respectively, for 20 minutes. Enzymatic activity is analyzed in the following buffers (final concentrations): human FXa (0.5 nM), rabbit FXa (2 nM), rat FXa (10 nM), or urokinase (4 nM) in 50 mM Tris–HCl buffer pH 8.3, 150 mM NaCl, and 0.1% bovine serum albumin (BSA); Pefachrome FXa (50–800 μM) or chromozym U (250 μM) with thrombin (0.69 nM), trypsin (2.2 nM), or plasmin (3.2 nM) in 0.1 μM Tris–HCl, pH 8.0, and 20 mM CaCl2; chromozym TH (200 μM), chromozym plasmin (500 μM), or chromozym trypsin (500 μM) with FXIa (1 nM) or APC (10 nM) in 50 mM phosphate buffer, pH 7.4, 150 mM NaCl; and S 2366 (150 or 500 μM) with FVIIa (1 nM) and tissue factor (3 nM) in 50 mM Tris–HCl buffer,pH 8.0, 100 mM NaCl, 5 mM CaCl2 and 0.3% BSA, H-D-Phe-Pro-Arg-6-amino-1-naphthalene-benzylsulfonamide-Water (100 μM) and measured for 3 hours. The FIXaβ/FX assay, comprising FIXaβ (8.8 nM) and FX (9.5 nM) in 50 mM Tris–HCl buffer, pH 7.4, 100 mM NaCl, 5 mM CaCl2 and 0.1% BSA, is started by the addition of I-1100 (50 μM), and measured for 60 minutes. The inhibitory constant (Ki) against FXa is calculated according to the Cheng–Prusoff equation. The IC50 is the amount of inhibitor required to diminish the initial velocity of the control by 50%.
体外活性在大鼠和兔的动静脉分流模型中,口服Rivaroxaban可减少动脉血栓形成（ED50：5.0 mg/kg和0.6 mg/kg）.在大鼠静脉瘀血模型实验中,静脉注射Rivaroxaban可剂量依赖地减少静脉血栓形成（ED50：0.1 mg/kg）.在狗0.3-3 mg/kg ,大鼠1-10 mg/kg的研究剂量范围内,Rivaroxaban血浆药代动力学呈线性.Rivaroxaban的血浆清除率较低: 狗 0.3 L/(kg·h) ,大鼠0.4 L/(kg·h) ;分布体积(V(ss))稳定: 狗0.4 L/kg,大鼠0.3 L/kg.Rivaroxaban在两种物种中口服的消除半衰期都比较短 (0.9-2.3 h).
体内活性Rivaroxaban是一种直接抑制活化X因子口服抑制剂（Ki：0.4 nM）,同时对凝血酶原酶活性也有抑制作用（IC50：2.1 nM）,用于动静脉血栓生成的预防和治疗。对于纯化的人源和兔源FXa,Rivaroxaban亲和性类似（IC50：0.7 nM和0.8 nM）, 但对于大鼠FXa亲和性较差（IC50：3.4 nM）。在血浆中, Rivaroxaban对人和兔内源FXa抑制效果相当（IC50：21 nM）,但在大鼠血浆中的抑制效果较差（IC50：290 nM）。在Caco-2细胞中,Rivaroxaban是具有极化运输特性和高渗透性的P-gp底物, 在体外实验中,即使到100 μM仍然不影响P-gp介导的药物运输。
存储条件Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
溶解度H2O : < 1 mg/mL (insoluble or slightly soluble)
DMSO : 81 mg/mL (185.8 mM)
Ethanol : < 1 mg/mL (insoluble or slightly soluble)
关键字Fxa | Inhibitor | Factor Xa | Rivaroxaban | inhibit
相关产品Dabigatran Etexilate Mesylate | Heparin sodium salt | 2-Methoxyphenothiazine | Coumarin | Thrombin (MW 37kDa) | (S)-(+)-Ibuprofen | Menadione | Ozagrel | AEBSF hydrochloride
相关库抑制剂库 | 经典已知活性库 | 已知活性化合物库 | 活性脂质化合物库 | EMA 上市药物库 | 高选择性抑制剂库 | 蛋白酶抑制剂库 | FDA 上市药物库 | 临床期小分子药物库 | 药物功能重定位化合物库
BAY 59-7939|||利伐沙班

公司简介

上海陶术生物科技有限公司为美国Target Molecule Corp. ( Target Mol ) 在上海建立的全资子公司。我们与美国波士顿、德国慕尼黑的同事一起，为北美、欧洲和亚洲从事药物研发和生物学研究的科学家提供优质的产品和专业的服务。公司下设筛选事业部，化学事业部，生物事业部和新材料部。 从虚拟筛选到实体化合物分子供应；从商业化产品销售到个性化定制合成；从对明确靶点的分子筛选到对明确分子的多靶点筛选，从高通量筛选到化学结构优化，我们都可以满足您的科研用品及技术服务的需求。 经过在中国市场五年的精心耕耘，我们已成为筛选化合物领域优秀的供应商，为超过五百家学校和各类企业提供了品质卓越的小分子化合物和药物筛

成立日期 (12年)
注册资本 566.2651万人民币
员工人数 100-500人
年营业额 ￥ 1亿以上
经营模式 贸易,试剂,定制,服务
主营行业 化学试剂,生物活性小分子

利伐沙班相关厂家报价 更多

  • 366789-02-8
  • 366789-02-8
  • 湖北威德利化学试剂有限公司 VIP
  • 2024-09-14
  • 询价
  • 利伐沙班
  • 利伐沙班
  • 武汉弘德悦欣医药科技有限公司 VIP
  • 2024-09-14
  • 询价
内容声明
进入官方账号
拨打电话 立即询价